References
  1. International Agency for Research on Cancer. Global cancer observatory: cancer today [EB/OL]. [2022 -06 -22].https://gco.iarc.fr/today/online-analysis-table.
  2. Zheng R,Zhang S,Zeng H,et al. Cancer incidence and mortality in China,2016[J]. J Natl Cancer Cent,2022,2(1):1-9.
  3. Bras A L,Gomes D,Filipe P A,et al.Trends,seasonality and forecast of pulmonary Tuberculosis in Portugal.[J].International Journal of Tuberculosis &Lung Disease,2014,18 (18):1202-1210.
  4. LUGO⁃VILLARINO G,TROEGELER A,BALBOA L,et al. The C⁃type lectin receptor DC⁃SIGN has an anti⁃inflammatory role in human M(IL ⁃ 4)macrophages in response to Mycobacterium tuberculosis[J]. Front Immunol,2018,9:1123.
  5. AN X,LI W,PAN L,et al. Lewis lung cancer cells promote SIGNR1(CD209b)⁃mediated macrophages polarization induced by IL⁃4 to facilitate immune evasion[J]. JCell Biochem,2016,117(5):1158-1166.
  6. YU Y H,LIAO C C,HSU W H,et al. Increased lung cancer risk among patients with pulmonary tuberculosis:a population cohortstudy[J]. J Thorac Oncol,2011,6(1):32-37.
  7. NALBANDIAN A,YAN B S,PICHUGIN A,et al. Lung carcinogenesis induced by chronic tuberculosis infection:the experimental model and genetic control[J]. Oncogene,2009,28(17):1928-1938
  8. QIANG L,WANG J,ZHANG Y,et al. Mycobacterium tuberculosis Mce2E suppresses the macrophage innate immune response and promotes epithelial cell proliferation[J]. Cell Mol Immunol,2019,16(4):380-391
  9. Shaodi Wen, Bo Shen. Immunotherapy mechanism and clinical research status of non-small cell lung cancer [J] Journal of Nanjing Medical University (Natural Science Edition), 2020, 40 (11): 1739-1746ZAEMES J,KIM C. Immune checkpoint inhibitor use and tuberculosis:a systematic review of the literature[J]. Eur J Cancer,2020,132:168-175
  10. CHRISTOPOULOS A,SAIF M W,SARRIS E G,et al. Epidemiology of active tuberculosis in lung cancer patients:a systematic review[J]. Clin Respir J,2014,8(4):375-381.
  11. Takwoingi Y, Whitworth H, Rees-Roberts M, et al. Interferon gamma release assays for Diagnostic Evaluation of Activetuberculosis(IDEA):test accuracy study and economic evaluation. Health Technol Assess,2019,23(23):1-152.doi:10.3310/hta23230.
  12. Lang S, Sun J, Wang X, et al. Asymptomatic pulmonary tuberculosis mimicking lung cancer on imaging: A retrospective study. Exp Ther Med,2017,14(3):2180-2188.doi:10.3892/etm.2017.4737.
  13. Henschke CI, Yankelevitz DF, Miettinen OS. Computed tomographic screening for lung cancer:the relationship of disease stage to tumor size.Arch Intern Med,2006,166(3):321-325.
  14. Wen Limin, Hou Dailun. Current status and progress of imaging evaluation methods for detecting pulmonary tuberculosis combined with lung cancer. Chin J Antituberc, June 2023, Vol. 45, No.6.
  15. Niyonkuru A, Chen X, Bakari KH, et al. Evaluation of the diagnostic efficacy of 18F-Fluorine-2-Deoxy-D-Glucose PET/CT for lung cancer and pulmonary tuberculosis in a Tuberculosisendemic Country. Cancer Med,2020,9(3):931-942.
  16. Guangchuan Dai, Chunyang Yin, Shanshan Chen, et al. One case had coexisting tuberculosis and lung cancer in the same lesion. Collection of papers of the 34th National Academic conference of the Chinese anti-tuberculosis Association.
  17. Sipei Zhang,Lijuan Chen,Jianwen Qin,et al. Discussion on drug use in a patient with lung adenocarcinoma complicated with active pulmonary tuberculosis: a case report. Journal of Tianjin Medical University, Volume 29, Issue 4, July 2023.
  18. Zelin Xiao, Jianqi Gao, Jiajie Liu,et al. Prognostic significance of surgical treatment in patients with NSCLC complicated with active pulmonary tuberculosis. Chinese Journal of Lung Diseases (electronic edition) June 2022, Volume 15, Issue 3.
  19. Guidelines for the Diagnosis and treatment of liver injury with anti-tuberculosis drugs, Chinese Association of Tuberculosis Society (2019 edition).
  20. Xiaoxin He, Bo Li and Lin Zhou. ”Observation on the efficacy of 4-month anti-tuberculosis treatment regimen containing Rifapentine” Interpretation of Chinese Journal of National Defense Consumption, December 2021, volume 43, Issue 12.
  21. Rui Jiao Ma, Zhili Jia, Xuefang Wang,et al. Comparative study of liver toxicity of anti-tuberculosis drugs based on zebrafish model Chinese Journal of Antibiotics September 2020 Vol.45, No.9.
  22. Expert consensus on the treatment of chronic kidney disease complicated with tuberculosis by Chinese Society of Tuberculosis (2022 edition).
  23. Zhenzhu Zhu Functional Design and Mechanism of Action of platinum-based
drugs against tumor, Doctoral Dissertation, Inorganic Chemistry, Nanjing University, May 1, 2016.